Iatrogene Vorhofseptumdefekte – klinische Relevanz?

Abstract

Transseptal catheterization is used by cardiologists to gain access in the left atrium. Over the last two decades, there has been renewed interest in the use of the transeptal puncture approach during the treatment of structural or electrophysiologic heart disease. This article gives an overview of the frequency and relevance of iatrogenic atrial septal defects.

• Literatur

• 1 Liu TJ, Lai HC, Lee WL et al. Immediate and late outcomes of patients undergoing transseptal left-sided heart catheterization for symptomatic valvular and arrhythmic diseases. Am Heart J 2006; 151: 235-241
• 2 De Ponti R, Cappato R, Curnis A et al. Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years. J Am Coll Cardiol 2006; 47: 1037-1042
• 3 Harikrishnan S, Titus T, Tharakan JM. Septal defects after percutaneous mitral valvotomy – all are not innocent. Int J Cardiol 2005; 99: 329-330
• 4 Nakao M, Ch'ng JK, Sin YK et al. Acquired right-to-left shunt through an atrial septal perforation with cyanosis after percutaneous transvenous mitral commissurotomy. J Am Soc Echocardiogr 2005; 18: 183-184
• 5 L'Epine Y, Drobinski G, Sotirov Y et al. Right heart failure due to an inter-atrial shunt after percutaneous mitral balloon dilatation. Eur Heart J 1989; 10: 285-287
• 6 Zanchetta M, Onorato E, Rigatelli G et al. Use of Amplatzer septal occluder in a case of residual atrial septal defect causing bidirectional shunting after percutaneous Inoue mitral balloon valvuloplasty. J Invasive Cardiol 2001; 13: 223-226
• 7 McCready JW, Moon JC, Chow AW. Right to left shunt following radiofrequency catheter ablation of atrial fibrillation in a patient with complex congenital heart disease. Europace 2010; 12: 289-290
• 8 Pitcher A, Schrale RG, Mitchell AR et al. Percutaneous closure of an iatrogenic atrial septal defect. Eur J Echocardiogr 2008; 9: 294-295
• 9 Fraker Jr TD, Harris PJ, Behar VS et al. Detection and exclusion of interatrial shunts by two-dimensional echocardiography and peripheral venous injection. Circulation 1979; 59: 379-384
• 10 Hausmann D, Daniel WG, Mügge A et al. Value of transesophageal color Doppler echocardiography for detection of different types of atrial septal defect in adults. J Am Soc Echocardiogr 1992; 5: 481-488
• 11 Hoey ET, Gopalan D, Ganesh V et al. Atrial septal defects. magnetic resonance and computed tomography appearances. J Med Imaging Radiat Oncol 2009; 53: 261-270
• 12 Inoue K, Owaki T, Nakamura T et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87: 394-402
• 13 Vahanian A, Baumgartner H, Bax J et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines on the management of valvular heart disease. Eur Heart J 2007; 28: 230-268
• 14 Vahanian A, Cormier B, Iung B. Percutaneous transvenous mitral commissurotomy using the Inoue balloon. international experience. Cathet Cardiovasc Diagn 1994; 2: 8-15
• 15 Bouleti C, Iung B, Laouénan C et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation 2012; 125: 2119-2127
• 16 McKay CR, Kawanishi DT, Rahimtoola SH. Catheter balloon valvuloplasty of the mitral valve in adults using a double-balloon technique. Early hemodynamic results. JAMA 1987; 257: 1753-1761
• 17 Casale P, Block PC, O'Shea JP et al. Atrial septal defect after percutaneous mitral balloon valvuloplasty: immediate results and follow-up. J Am Coll Cardiol 1990; 15: 1300-1304
• 18 Yoshida K, Yoshikawa J, Akasaka T et al. Assessment of left-to-right atrial shunting after percutaneous mitral valvuloplasty by transesophageal color Doppler flow-mapping. Circulation 1989; 80: 1521-1526
• 19 Cequier A, Bonan R, Dyrda I et al. Atrial shunting after percutaneous mitral valvuloplasty. Circulation 1990; 81: 1190
• 20 Daniel WG, Baumgartner H, Gohlke-Bärwolf C et al. Klappenvitien im Erwachsenenalter. Clin Res Cardiol 2006; 95: 620-641
• 21 Feldman T, Wasserman HS, Herrmann HC et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 2005; 46: 2134-2140
• 22 Feldman T, Kar S, Rinaldi M et al. EVEREST Investigators. ercutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009; 54: 686-694
• 23 Feldman T, Foster E, Glower DD et al. EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
• 24 Biner S, Siegel RJ, Feldman T et al. EVEREST investigators. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail 2012; 14: 939-945
• 25 Smith T, McGinty P, Bommer W et al. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv 2012; 80: 678-685
• 26 Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375
• 27 Chugh SS, Blackshear JL, Shen WK et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378
• 28 Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. Cardiol Clin 2008; 26: 267-275
• 29 Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764
• 30 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
• 31 Camm AJ, Kirchhof P, Lip GYH. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
• 32 ACTIVE WritingGroup of the ACTIVE Investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912
• 33 Connolly SJ, Pogue J, Hart RG. ACTIVE Investigators et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078
• 34 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419
• 35 Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
• 36 Wallentin L, Yusuf S, Ezekowitz MD et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983
• 37 Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 2000; 160: 41-46
• 38 Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759
• 39 Klein AL, Grimm RA, Murray RD et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420
• 40 Healey JS, Crystal E, Lamy A et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005; 150: 288-293
• 41 Bayard YL, Omran H, Neuzil P et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010; 6: 220-226
• 42 Viles-Gonzalez JF, Kar S, Douglas P et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012; 59: 923-929
• 43 Landmesser U, Holmes Jr DR. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2012; 33: 698-704
• 44 Omran H, Hardung D, Schmidt H et al. Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol 2003; 14: 56-59
• 45 Singh SM, Douglas PS, Reddy VY. The incidence and long-term clinical outcome of iatrogenic atrial septal defects secondary to transseptal catheterization with a 12F transseptal sheath. Circ Arrhythm Electrophysiol 2011; 4: 166-171
• 46 Rillig A, Meyerfeldt U, Birkemeyer R et al. Persistent iatrogenic atrial septal defect after pulmonary vein isolation: incidence and clinical implications. J Interv Card Electrophysiol 2008; 22: 177-181
• 47 Hammerstingl C, Lickfett L, Jeong KM et al. Persistence of iatrogenic atrial septal defect after pulmonary vein isolation – an underestimated risk?. Am Heart J 2006; 152: 362